Literature DB >> 29237684

Harnessing the Power of Pharmacometabolomics: The Metabolic Footprint of Statins.

Jennifer E Ho1.   

Abstract

Entities:  

Keywords:  Editorials; Mendelian randomization analysis; cholesterol; lovastatin; pravastatin

Mesh：

Substances：

Year:  2017        PMID： 29237684      PMCID： PMC5734675          DOI： 10.1161/CIRCGENETICS.117.002014

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN： 1942-3268


× No keyword cloud information.
  10 in total

1.  Remnant cholesterol as a causal risk factor for ischemic heart disease.

Authors:  Anette Varbo; Marianne Benn; Anne Tybjærg-Hansen; Anders B Jørgensen; Ruth Frikke-Schmidt; Børge G Nordestgaard
Journal:  J Am Coll Cardiol       Date:  2012-12-19       Impact factor: 24.094

2.  Pharmacometabolomics Meets Genetics: A "Natural" Clinical Trial of Statin Effects.

Authors:  Deepak Voora; Svati H Shah
Journal:  J Am Coll Cardiol       Date:  2016-03-15       Impact factor: 24.094

3.  Statin Effects on Metabolic Profiles: Data From the PREVEND IT (Prevention of Renal and Vascular End-stage Disease Intervention Trial).

Authors:  Daniel Kofink; Ruben N Eppinga; Wiek H van Gilst; Stephan J L Bakker; Robin P F Dullaart; Pim van der Harst; Folkert W Asselbergs
Journal:  Circ Cardiovasc Genet       Date:  2017-12

4.  Metabolite profiles and the risk of developing diabetes.

Authors:  Thomas J Wang; Martin G Larson; Ramachandran S Vasan; Susan Cheng; Eugene P Rhee; Elizabeth McCabe; Gregory D Lewis; Caroline S Fox; Paul F Jacques; Céline Fernandez; Christopher J O'Donnell; Stephen A Carr; Vamsi K Mootha; Jose C Florez; Amanda Souza; Olle Melander; Clary B Clish; Robert E Gerszten
Journal:  Nat Med       Date:  2011-03-20       Impact factor: 53.440

5.  Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012.

Authors:  Qiuping Gu; Ryne Paulose-Ram; Vicki L Burt; Brian K Kit
Journal:  NCHS Data Brief       Date:  2014-12

Review 6.  Interpretation of the evidence for the efficacy and safety of statin therapy.

Authors:  Rory Collins; Christina Reith; Jonathan Emberson; Jane Armitage; Colin Baigent; Lisa Blackwell; Roger Blumenthal; John Danesh; George Davey Smith; David DeMets; Stephen Evans; Malcolm Law; Stephen MacMahon; Seth Martin; Bruce Neal; Neil Poulter; David Preiss; Paul Ridker; Ian Roberts; Anthony Rodgers; Peter Sandercock; Kenneth Schulz; Peter Sever; John Simes; Liam Smeeth; Nicholas Wald; Salim Yusuf; Richard Peto
Journal:  Lancet       Date:  2016-09-08       Impact factor: 79.321

7.  Application of new cholesterol guidelines to a population-based sample.

Authors:  Michael J Pencina; Ann Marie Navar-Boggan; Ralph B D'Agostino; Ken Williams; Benjamin Neely; Allan D Sniderman; Eric D Peterson
Journal:  N Engl J Med       Date:  2014-03-19       Impact factor: 91.245

8.  Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase.

Authors:  Peter Würtz; Qin Wang; Pasi Soininen; Antti J Kangas; Ghazaleh Fatemifar; Tuulia Tynkkynen; Mika Tiainen; Markus Perola; Therese Tillin; Alun D Hughes; Pekka Mäntyselkä; Mika Kähönen; Terho Lehtimäki; Naveed Sattar; Aroon D Hingorani; Juan-Pablo Casas; Veikko Salomaa; Mika Kivimäki; Marjo-Riitta Järvelin; George Davey Smith; Mauno Vanhala; Debbie A Lawlor; Olli T Raitakari; Nish Chaturvedi; Johannes Kettunen; Mika Ala-Korpela
Journal:  J Am Coll Cardiol       Date:  2016-03-15       Impact factor: 24.094

9.  Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism.

Authors:  Anna Helgadottir; Solveig Gretarsdottir; Gudmar Thorleifsson; Hilma Holm; Riyaz S Patel; Thorarinn Gudnason; Gregory T Jones; Andre M van Rij; Danny J Eapen; Annette F Baas; David-Alexandre Tregouet; Pierre-Emmanuel Morange; Joseph Emmerich; Bengt Lindblad; Anders Gottsäter; Lambertus A Kiemeny; Jes S Lindholt; Natzi Sakalihasan; Robert E Ferrell; David J Carey; James R Elmore; Philip S Tsao; Niels Grarup; Torben Jørgensen; Daniel R Witte; Torben Hansen; Oluf Pedersen; Roberto Pola; Eleonora Gaetani; Hulda B Magnadottir; Cisca Wijmenga; Gerard Tromp; Antti Ronkainen; Ynte M Ruigrok; Jan D Blankensteijn; Thomas Mueller; Philip S Wells; Javier Corral; Jose Manuel Soria; Juan Carlos Souto; John F Peden; Shapour Jalilzadeh; Bongani M Mayosi; Bernard Keavney; Rona J Strawbridge; Maria Sabater-Lleal; Karl Gertow; Damiano Baldassarre; Kristiina Nyyssönen; Rainer Rauramaa; Andries J Smit; Elmo Mannarino; Philippe Giral; Elena Tremoli; Ulf de Faire; Steve E Humphries; Anders Hamsten; Vilhelmina Haraldsdottir; Isleifur Olafsson; Magnus K Magnusson; Nilesh J Samani; Allan I Levey; Hugh S Markus; Konstantinos Kostulas; Martin Dichgans; Klaus Berger; Gregor Kuhlenbäumer; E Bernd Ringelstein; Monika Stoll; Udo Seedorf; Peter M Rothwell; Janet T Powell; Helena Kuivaniemi; Pall T Onundarson; Einar Valdimarsson; Stefan E Matthiasson; Daniel F Gudbjartsson; Guðmundur Thorgeirsson; Arshed A Quyyumi; Hugh Watkins; Martin Farrall; Unnur Thorsteinsdottir; Kari Stefansson
Journal:  J Am Coll Cardiol       Date:  2012-08-21       Impact factor: 24.094

10.  Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.

Authors:  Stephen A Williams; Ashwin C Murthy; Robert K DeLisle; Craig Hyde; Anders Malarstig; Rachel Ostroff; Sophie J Weiss; Mark R Segal; Peter Ganz
Journal:  Circulation       Date:  2017-10-03       Impact factor: 29.690
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.